Navigation Links
Codexis Names David Anton VP Bioindustrials R&D
Date:3/25/2008

REDWOOD CITY, Calif., March 25 /PRNewswire/ -- Codexis, Inc., today announced the appointment of David Anton, Ph.D. to the newly-created position of Vice President, Bioindustrials Research and Development. He joins Codexis from DuPont, where he was Venture Manager, Biofuels. He will report to Alan Shaw, Ph.D., President and CEO.

"Codexis targets major global energy and environmental markets where clean technology can make a significant impact," said Alan Shaw, Ph.D., President and CEO. "We are currently working with Shell in the development of biofuels, and expect to apply our technology to other potential new bioindustrial applications, such as carbon capture and storage, waste water purification and cleaner chemical manufacturing."

"Dr. Anton has over 25 years experience directing the development of new technology solutions and production processes at one of the world's largest science companies," Dr. Shaw added. "His experience as a scientist and venture manager in bioindustrials can make an important, immediate contribution to this important Codexis business. We are pleased to expand our management team with such a well known and broadly-experienced research executive."

Dr. Anton joined DuPont in 1983 and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He is a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com.

Contact: Justin Jackson, jjackson@burnsmc.com, Burns McClellan, 212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
2. Rothwell, Wolf Elected to Codexis Board
3. Codexis Opens Singapore Laboratory
4. Bruce Pasternack Elected to Codexis Board
5. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
6. Codexis Appoints Singapore Laboratories Managing Director
7. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
8. Cato Research Names John Cline as President
9. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
10. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Development, Europe. Based in Paris, he will focus on acquiring new accounts and ... being met. , “Fred brings to our European clients more than ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... ... strategic changes over the years and Open Access publishing is one of the ... With its 700+ open access journals and 3000+ International Conferences ...
(Date:2/9/2016)... Feb. 9, 2016  DNAtrix, a clinical ... cancer, announced that its lead product, DNX-2401, ... as an orphan medicinal product for the ... of glioma, strikes approximately 25,000 people a ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):